Get the Stockscreener App
0.5177
4.66%
-0.0253
After Hours:
.50
-0.0177
-3.42%
Plus Therapeutics Inc stock is traded at $0.5177, with a volume of 3.72M.
It is down -4.66% in the last 24 hours and down -29.20% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.543
Open:
$0.5473
24h Volume:
3.72M
Relative Volume:
0.18
Market Cap:
$51.39M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2046
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-14.05%
1M Performance:
-29.20%
6M Performance:
-20.10%
1Y Performance:
-61.65%
1-Day Range:
$0.5036
$0.552
1-Week Range:
$0.486
$0.6149
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.5177 | 53.90M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Is Plus Therapeutics Inc. forming a reversal patternJuly 2025 Trends & Weekly Market Pulse Alerts - newser.com
How interest rate cuts could boost Plus Therapeutics Inc. stock2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Is Plus Therapeutics Inc. forming a bottoming baseEarnings Recap Report & Advanced Swing Trade Entry Alerts - newser.com
Will Plus Therapeutics Inc. stock gain from strong economyPortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Will Plus Therapeutics Inc. outperform the marketBreakout Watch & Verified Technical Trade Signals - newser.com
Plus Therapeutics stock price target lowered to $2 at H.C. Wainwright - Investing.com UK
Smart tools for monitoring Plus Therapeutics Inc.’s price action2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
Plus Therapeutics (PSTV) Analyst Rating Update: Price Target Low - GuruFocus
HC Wainwright & Co. Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Order flow analysis tools used on Plus Therapeutics Inc.Insider Buying & Step-by-Step Swing Trade Plans - newser.com
Can Plus Therapeutics Inc. rally from current levelsJuly 2025 Levels & Daily Oversold Bounce Ideas - newser.com
Applying Wyckoff theory to Plus Therapeutics Inc. stock2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will Plus Therapeutics Inc. benefit from macro trendsGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
How Plus Therapeutics Inc. (XMP0) stock compares with tech leadersTrade Entry Report & Smart Money Movement Tracker - newser.com
What MACD signals say about Plus Therapeutics Inc.2025 Trade Ideas & Weekly Breakout Opportunity Watchlist - newser.com
Can a trend reversal in Plus Therapeutics Inc. lead to recoveryMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Candlestick signals on Plus Therapeutics Inc. stock todayQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
Should you hold or exit Plus Therapeutics Inc. nowTrend Reversal & Daily Momentum Trading Reports - newser.com
Why Plus Therapeutics Inc. stock remains on watchlistsRisk Management & Daily Risk Controlled Trade Plans - newser.com
Applying Elliott Wave Theory to Plus Therapeutics Inc.Market Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Is Plus Therapeutics Inc. stock positioned for long term growthMarket Risk Report & Real-Time Market Trend Scan - newser.com
What momentum shifts mean for Plus Therapeutics Inc.Market Sentiment Review & Verified Technical Trade Signals - newser.com
Is Plus Therapeutics Inc. (XMP0) stock attractive for growth funds2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
Can Plus Therapeutics Inc. stock outperform in 2025 bull marketQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Buy" by Brokerages - MarketBeat
How to use Fibonacci retracement on Plus Therapeutics Inc.July 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Is Plus Therapeutics Inc. stock positioned for digital transformation2025 Year in Review & Daily Momentum Trading Reports - newser.com
D. Boral Capital Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - MarketBeat
Is Plus Therapeutics Inc. stock dividend yield sustainableQuarterly Profit Report & Technical Entry and Exit Tips - newser.com
MSN Money - MSN
Plus Therapeutics’ ARISE Study: A New Hope for Fertility Treatment - MSN
Is Plus Therapeutics Inc. (XMP0) stock protected from inflationJuly 2025 Analyst Calls & Scalable Portfolio Growth Ideas - newser.com
Plus Therapeutics (NASDAQ:PSTV) Issues Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
PSTV: Analyst Maintains 'Buy' Rating and $5 Price Target Today | - GuruFocus
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
What MACD and RSI say about Plus Therapeutics Inc.Quarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Plus: Q3 Earnings Snapshot - Stamford Advocate
Why Plus Therapeutics Inc. stock could outperform in 20252025 AllTime Highs & Accurate Trade Setup Notifications - newser.com
Multi factor analysis applied to Plus Therapeutics Inc.July 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - newser.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):